HL-07 is under clinical development by Huons Global and currently in Phase I for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Phase I drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HL-07’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HL-07 is under development for the treatment of dry eye syndrome. The drug candidate is developed based on gene recombinant production technology using E. coli fermentation. It is based on recombinant protein thymosin beta 4 (TB4) peptide. TB4 is a synthetic version of a naturally occurring peptide.
Huons Global overview
Huons Global (Huons) is a pharmaceutical company that provides medical solutions for human health. The company carries out development, manufacture and distribution of pharmaceutical products and medical devices. Its product portfolio includes a wide range of ethical drugs, over the counter drugs, healthcare foods and medical devices. Huons offers its products in various formulations such as capsules, tablets, vials, suspensions, syrup, injections and eye drops. It also offers custom manufacturing services to manufacture a wide variety of pharmaceutical products. It markets its products in the markets of Latin America, the US, Asia, Middle East, Africa, and Europe. Huons is headquartered in Seongnam, Gyeonggi, South Korea .
For a complete picture of HL-07’s drug-specific PTSR and LoA scores, buy the report here.